How we treat mature B-cell neoplasms (indolent B-cell lymphomas)
Journal of Hematology & Oncology, 2021 Mature B cell neoplasms, previously indolent non-Hodgkin lymphomas (iNHLs), are a heterogeneous group of malignancies sharing similar disease courses and treatment paradigms. Most patients with iNHL have an excellent prognosis, and in many, treatment can
Melissa Lumish +5 more
doaj +1 more source
Lymphoma caused by intestinal microbiota. [PDF]
, 2014 The intestinal microbiota and gut immune system must constantly communicate to maintain a balance between tolerance and activation: on the one hand, our immune system should protect us from pathogenic microbes and on the other hand, most of the millions ...
Schiestl, Robert H, Yamamoto, Mitsuko L
core +2 more sources
Experimental Hematology & Oncology, 2023 Background Cell cycle dysregulation characterized by cyclin D1 overexpression is common in mantle cell lymphoma (MCL), while mitotic disorder was less studied. Cell division cycle 20 homologue (CDC20), an essential mitotic regulator, was highly expressed
Yingtong Chen +9 more
doaj +1 more source
Agarose gel serum protein electrophoresis in cats with and without lymphoma and preliminary results of tandem mass fingerprinting analysis [PDF]
, 2011 <b>Background</b>: Serum electrophoretic profiles in cats are poorly characterized with respect to the protein components of the globulin fractions, and interpretation of the electrophoretograms has routinely been done in ignorance of the ...
Baker +36 more
core +1 more source
Qualitative results from a phase II pilot randomised controlled trial of a lymphoma nurse-led model of survivorship care [PDF]
, 2018 Purpose: To explore and describe lymphoma survivors’ thoughts and perceptions of the components of a nurse led lymphoma survivorship clinic intervention. Methods: An exploratory, qualitative descriptive study using interviews from 10 participants who had
Bulsara, Caroline +2 more
core +2 more sources
Cell Death and Disease, 2023 Bruton’s tyrosine kinase inhibitors (BTKi) and CAR T-cell therapy have demonstrated tremendous clinical benefits in mantle cell lymphoma (MCL) patients, but intrinsic or acquired resistance inevitably develops.
Yijing Li +15 more
doaj +1 more source
Inhibition of oncogenic transcription factor REL by the natural product derivative calafianin monomer 101 induces proliferation arrest and apoptosis in human B-lymphoma cell lines [PDF]
, 2015 Increased activity of transcription factor NF-κB has been implicated in many B-cell lymphomas. We investigated effects of synthetic compound calafianin monomer (CM101) on biochemical and biological properties of NF-κB.
Chennamadhavuni, Spandan +4 more
core +2 more sources
BCL-W has a fundamental role in B cell survival and lymphomagenesis. [PDF]
, 2017 Compromised apoptotic signaling is a prerequisite for tumorigenesis. The design of effective therapies for cancer treatment depends on a comprehensive understanding of the mechanisms that govern cell survival.
Annette S. Kim +14 more
core +2 more sources
MALT1, BCL10 and FOXP1 in salivary gland mucosa-associated lymphoid tissue lymphomas [PDF]
, 2006 In view of the certain anatomic site-dependent frequency of chromosomal translocations involved in extranodal marginal zone B cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) pathogenesis, 17 salivary gland MALT lymphoma cases were ...
Isaacson PG +8 more
core +1 more source
A Phase I/II first-line study of R-CHOP plus B-cell receptor/NF-κB-double-targeting to molecularly assess therapy response [PDF]
, 2019 The ImbruVeRCHOP trial is an investigator-initiated, multicenter, single-arm, open label Phase I/II study for patients 61-80 years of age with newly diagnosed CD20+ diffuse large B-cell lymphoma and a higher risk profile (International Prognostic Index ...
Anagnostopoulos, Ioannis +7 more
core +2 more sources